Bioproduction tools company BioLife Solutions Inc (NASDAQ:BLFS) said on Wednesday that its new SciSafe division has announced a two year contract for cold chain management and storage of COVID-19 vaccines.
The two year contract, valued at approximately USD2.7m, is awarded by a large pharmaceutical client.
In addition, the management expects SciSafe to contribute approximately USD9m in incremental revenue in 2021.
Founded in 2010, SciSafe offers dedicated pharmaceutical and biological specimen storage in its four fully cGMP-compliant state-of-the-art sample management facilities. Its clients have repeatedly chosen to store their most valued and irreplaceable biological samples.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine